RTRosa Weiss Telles

Rosa Weiss Telles

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rosa Weiss Telles has a total of 202 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Strengthening health systems to prioritise, provide care, and prevent osteoarthritis: a roadmap for global health policy

    by Andrew M Briggs, Jocelyn L Bowden, May Arna Risberg, Marita Cross, Leigh F Callahan, Cindy L Copenhaver, Krysia S Dziedzic, Rolando Espinosa-Morales, Kai Fu, Francis Guillemin, et al.

  • Open Access

    Adverse childhood experiences and adulthood physical performance: the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)

    by Rodrigo Pinto, Sandhi Maria Barreto, Amanda Viana Machado, Ana Luísa Patrão, Luana Giatti, Rosane Harter Griep, Rosa Weiss Telles, Lidyane Do Valle Camelo

    This study aimed to investigate associations between adverse childhood experiences (ACEs) and adulthood physical performance within a Brazilian population using a cross-sectional analysis. A total of 10,896 civil servants, aged 41 to 84 years, from the third wave of the Brazilian Longitudinal Study of Adult Health, were included in this research. ACEs were identified retrospectively using child labor and five household dysfunction indicators related to the first 14 years of life, analyzed individually and as a cumulative score. Physical performance was assessed using Short Physical Performance Battery, whose score was categorized as poor (≤ 7) or good (≥ 8) physical performance. Binary logistic regression models were employed. Participants had a mean age of 59 years (SD = 8.71), with 42% reporting exposure to at least 1 ACE and 28% having poor physical performance. After adjustments, exposure to one (OR = 1.18; 95%CI: 1.07; 1.32), two (OR = 1.19; 95%CI: 1.02; 1.39), and three or more ACEs types (OR = 1.36; 95%CI: 1.05; 1.75) increased poor physical performance chances in adulthood. Those who experienced household members conviction/incarceration (OR = 1.43; 95%CI: 1.02; 1.99), parental death (OR = 1.22; 95%CI: 1.05; 1.41) or separation/divorce (OR = 1.17; 95%CI: 1.01; 1.36) during childhood also had higher poor physical performance chances in adulthood. ACEs are associated with increased poor physical performance chances in adulthood. These findings underscore the importance of public policies aimed at reducing ACEs to alleviate the burden of diminished physical performance in adulthood.

  • Open Access

    Association between diabetes and frailty, and the moderating role of sex in that association in older adults of the ELSA-Brasil study

    by Elizabeth Leite Barbosa, Rosa Weiss Telles, Maria de Jesus Mendes da Fonseca, Maria Inês Schmidt, Sandhi Maria Barreto, Bruce Duncan, Rosane Harter Griep

  • Self-esteem and aesthetic plastic surgeries in patients with immune-mediated rheumatic diseases: results from a cross-sectional web survey

    by Anna Luiza Ferreira Maciel, Alice de Oliveira Andalécio Costa, Caio Carvalhais Chaves, Fabrício Pacheco, Bárbara Aguiar dos Santos, Nathália Estanislau Moreira, Ana Carolina de Moura Matosinhos, Cristina Costa Duarte Lanna, Rosa Weiss Telles, Fabiana de Miranda Moura, et al.


  • Validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Brazilian SLE patients

    by Clarice M Mata-Machado, Cristina C D Lanna, Juliana C Garrido, Odirlei A Monticielo, Evandro M Klumb, Guilherme L Tres, Fabiana M Moura, Rosa W Telles

    Objectives: To evaluate the measurement properties of SLE-DAS, using the Brazilian-Portuguese version (SLE-DAS Pt-BR). Methods: Cross-sectional, test-retest, multicentre study, that included patients ≥18 years old who met the classification criteria for SLE. Reliability was tested using type 2.1 intraclass correlation coefficient (ICC2.1), standard measurement error (SEM) and minimum detectable difference (MDD). For construct validity, Spearman correlation (rho) and/or percentage of agreement with χ2 test were used to correlate/associate SLE-DAS Pt-BR with SLEDAI-2K, PGA and the definitions of remission (DORIS) and low disease activity (LLDAS). Performance of SLE-DAS was assessed with PGA as reference standard, calculating sensitivity, specificity and accuracy. Results: A total of 365 patients were included: mean age 44.5 (SD 14.0) years, 92.9% female. 57.3% were in remission according to SLE-DAS Pt-BR. Excellent intra and inter-rater reliability was observed (ICC2.1 = 0.999 and 0.945, respectively), with acceptable SEM/MDD. There was a strong correlation between SLE-DAS Pt-BR with SLEDAI-2K (rho = 0.895) and PGA (rho = 0.861). Sensitivity, specificity and accuracy of SLE-DAS Pt-BR were above 90% for remission and moderate/severe disease activity and above 80% for mild activity. Most individuals in remission and in moderate/severe activity according to SLEDAI-2K were also in those categories according to SLE-DAS Pt-BR (99.5% and 77.9%, respectively). Considering mild activity concordance was observed in 42.9% patients. Most patients considered in DORIS remission and LLDAS were also in remission and in low disease activity by SLE-DAS Pt-BR. Conclusion: The present study demonstrated that the SLE-DAS Pt-BR is valid and capable of measuring SLE disease activity.


  • Top Cited Papers
    Open Access

    Risk factors for the development of knee osteoarthritis across the lifespan: A systematic review and meta-analysis

    by Vicky Duong, Christina Abdel Shaheed, Manuela L. Ferreira, Sujita W. Narayan, Venkatesha Venkatesha, David J. Hunter, Jimmy Zhu, Inoshi Atukorala, Sarah Kobayashi, Siew Li Goh, et al.


  • Open Access

    Life satisfaction and chronic musculoskeletal pain at the baseline of ELSA-Brasil MSK

    by Daniela Castelo Azevedo, Rosa Weiss Telles, Luciana Andrade Carneiro Machado, Sandhi Maria Barreto

    Objective: The aim of this study was to investigate the association between life satisfaction and the presence and severity of chronic musculoskeletal pain (CMP). Methods: In this cross-sectional study, a total of 2,756 participants (mean age: 55.8 years, standard deviation [SD]=8.9 years) at the baseline of the Brazilian Longitudinal Study of Adult Health Musculoskeletal cohort (2012-2014) completed the Satisfaction with Life Scale and were assessed for CMP (duration>6 months) at neck, shoulders, upper back, elbows, lower back, wrists/hands, hips/thighs, knees, and ankles/feet. CMP phenotypes were identified based on measures that considered pain-related disability (non-disabling/disabling), pain demand for a healthcare professional (non-troublesome/troublesome), and body pain spreading according to the number of sites (0, 1-2, and ≥3, multisite) and the number of regions (upper limbs, lower limbs, and axial skeleton) affected (0, 1-2, 3, generalized). The association of life satisfaction with CMP and each CMP phenotype was investigated by binomial and multinomial logistic regression analyses adjusted for sociodemographic lifestyle and clinical confounders. Results: Greater life satisfaction was associated with lower chances of CMP (odds ratio [OR]=0.95; 95% confidence interval [CI] 0.94-0.97), as well as across all CMP phenotypes. The strength of this association was slightly greater for disabling CMP (OR=0.94; 95%CI 0.92-0.96) compared to non-disabling CMP (OR=0.97; 95%CI 0.95-0.99), and for troublesome CMP (OR=0.96; 95%CI 0.94-0.97) compared to non-troublesome CMP (OR=0.94; 95%CI 0.94-0.98). This association also held true when considering individuals experiencing multisite pain (OR=0.93; 95%CI 0.91-0.95) compared to those with pain at 1-2 sites (OR=0.97; 95%CI 0.95-0.99), and considering generalized pain (OR=0.93; 95%CI 0.90-0.96) compared to pain in 1-2 regions (OR=0.96; 95%CI 0.95-0.98). Conclusion: Greater life satisfaction seems to decrease the chances of experiencing any, and especially more severe, CMP.

  • Open Access

    II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment

    by Edgard Torres dos Reis-Neto, Luciana Parente Costa Seguro, Emília Inoue Sato, Eduardo Ferreira Borba, Evandro Mendes Klumb, Lilian Tereza Lavras Costallat, Marta Maria das Chagas Medeiros, Eloisa Bonfá, Nafice Costa Araújo, Simone Appenzeller, et al.

    Objective: To develop the second evidence-based Brazilian Society of Rheumatology consensus for diagnosis and treatment of lupus nephritis (LN). Methods: Two methodologists and 20 rheumatologists from Lupus Comittee of Brazilian Society of Rheumatology participate in the development of this guideline. Fourteen PICO questions were defined and a systematic review was performed. Eligible randomized controlled trials were analyzed regarding complete renal remission, partial renal remission, serum creatinine, proteinuria, serum creatinine doubling, progression to end-stage renal disease, renal relapse, and severe adverse events (infections and mortality). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to develop these recommendations. Recommendations required ≥82% of agreement among the voting members and were classified as strongly in favor, weakly in favor, conditional, weakly against or strongly against a particular intervention. Other aspects of LN management (diagnosis, general principles of treatment, treatment of comorbidities and refractory cases) were evaluated through literature review and expert opinion. Results: All SLE patients should undergo creatinine and urinalysis tests to assess renal involvement. Kidney biopsy is considered the gold standard for diagnosing LN but, if it is not available or there is a contraindication to the procedure, therapeutic decisions should be based on clinical and laboratory parameters. Fourteen recommendations were developed. Target Renal response (TRR) was defined as improvement or maintenance of renal function (±10% at baseline of treatment) combined with a decrease in 24-h proteinuria or 24-h UPCR of 25% at 3 months, a decrease of 50% at 6 months, and proteinuria < 0.8 g/24 h at 12 months. Hydroxychloroquine should be prescribed to all SLE patients, except in cases of contraindication. Glucocorticoids should be used at the lowest dose and for the minimal necessary period. In class III or IV (±V), mycophenolate (MMF), cyclophosphamide, MMF plus tacrolimus (TAC), MMF plus belimumab or TAC can be used as induction therapy. For maintenance therapy, MMF or azathioprine (AZA) are the first choice and TAC or cyclosporin or leflunomide can be used in patients who cannot use MMF or AZA. Rituximab can be prescribed in cases of refractory disease. In cases of failure in achieving TRR, it is important to assess adherence, immunosuppressant dosage, adjuvant therapy, comorbidities, and consider biopsy/rebiopsy. Conclusion: This consensus provides evidence-based data to guide LN diagnosis and treatment, supporting the development of public and supplementary health policies in Brazil.